CLEC9A and neoplasm: C-type lectin domain family 9 A (CLEC9A)-cDC1+ DCs can regulate tumor immune surveillance and establish an important link between metabolism and immunity, serving as a therapeutic target for skin cancer (Zeng et al. 2023).